Healthcare / BiotechnologyStockholm
$0.45
+0.00 (+0.94%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-37.0M · quality 72.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
13/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$69M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-21.5%
↓Gross Margin
N/A
•Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
1.51x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-26.3M · FCF $-39.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | $-26.3M | $-26.3M | $-20.6M | $-16.5M | $-13.1M |
| EBITDA | $-25.3M | $-25.3M | $-20.3M | $-16.4M | $-13.1M |
| EPS | -0.25 | -0.25 | -0.23 | -0.41 | -0.44 |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Current Ratio | 1.37 | 1.37 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-39.6M | $-39.6M | $-37.0M | $-34.8M | $-26.9M |
| Returns | |||||
| ROE | -21.5% | -21.5% | -16.6% | -14.5% | -12.4% |
| Valuation | |||||
| P/B | 0.38 | 0.38 | 2.38 | 1.11 | 1.02 |
| Growth & Yield | |||||
| EPS Growth | -9.2% | -9.2% | 43.8% | 6.3% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-75.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.23 → -0.25
Residual
-75.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.